Galera Therapeutics (GRTX) Competitors $0.04 0.00 (0.00%) (As of 11/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GRTX vs. LCI, RDHL, NKGN, ENSC, SNGX, JAGX, ADXN, FBRX, EGRX, and GLTOShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Lannett (LCI), RedHill Biopharma (RDHL), NKGen Biotech (NKGN), Ensysce Biosciences (ENSC), Soligenix (SNGX), Jaguar Health (JAGX), Addex Therapeutics (ADXN), Forte Biosciences (FBRX), Eagle Pharmaceuticals (EGRX), and Galecto (GLTO). These companies are all part of the "medical" sector. Galera Therapeutics vs. Lannett RedHill Biopharma NKGen Biotech Ensysce Biosciences Soligenix Jaguar Health Addex Therapeutics Forte Biosciences Eagle Pharmaceuticals Galecto Galera Therapeutics (NASDAQ:GRTX) and Lannett (NYSE:LCI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Is GRTX or LCI more profitable? Galera Therapeutics has a net margin of 0.00% compared to Lannett's net margin of -62.40%. Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -116.47% Lannett -62.40%N/A -13.39% Does the MarketBeat Community favor GRTX or LCI? Lannett received 410 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 58.08% of users gave Lannett an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote. CompanyUnderperformOutperformGalera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% LannettOutperform Votes46058.08% Underperform Votes33241.92% Which has stronger valuation & earnings, GRTX or LCI? Galera Therapeutics has higher earnings, but lower revenue than Lannett. Galera Therapeutics is trading at a lower price-to-earnings ratio than Lannett, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.58-0.07Lannett$340.58M0.00-$231.62M-$18.88N/A Which has more volatility & risk, GRTX or LCI? Galera Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, Lannett has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Does the media favor GRTX or LCI? In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Lannett'saverage media sentiment score. Company Overall Sentiment Galera Therapeutics Neutral Lannett Neutral Do institutionals & insiders believe in GRTX or LCI? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 40.3% of Lannett shares are held by institutional investors. 6.9% of Galera Therapeutics shares are held by insiders. Comparatively, 13.1% of Lannett shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryLannett beats Galera Therapeutics on 6 of the 11 factors compared between the two stocks. Ad True Gold RepublicCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.36M$6.45B$5.01B$8.72BDividend YieldN/A8.22%7.62%4.07%P/E Ratio-0.074.5982.7813.06Price / SalesN/A376.951,392.0188.46Price / CashN/A22.1633.0332.45Price / Book-0.025.354.604.60Net Income-$59.08M$152.87M$117.53M$225.14M7 Day PerformanceN/A-8.74%-3.16%-1.82%1 Month PerformanceN/A-9.67%-4.58%-0.78%1 Year PerformanceN/A25.97%29.14%23.20% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.04flatN/A-71.3%$2.36MN/A-0.0730Gap DownLCILannettN/AN/AN/AN/A$7.38M$340.58M-0.04810High Trading VolumeRDHLRedHill Biopharma1.3198 of 5 stars$6.99-4.1%N/A-96.6%$9.34M$6.53M0.00210News CoveragePositive NewsNKGNNKGen BiotechN/A$0.30+11.2%N/A-89.4%$9.33M$80,000.00-0.06N/AHigh Trading VolumeENSCEnsysce Biosciences0.457 of 5 stars$0.68+1.5%N/A-24.9%$9.30M$2.23M-0.3710Earnings ReportSNGXSoligenix1.0142 of 5 stars$3.52-0.6%N/A-44.9%$8.88M$840,000.00-0.4720JAGXJaguar Health0.5606 of 5 stars$0.98+2.1%N/A-96.0%$8.87M$9.76M0.0050Gap UpADXNAddex Therapeutics2.5954 of 5 stars$7.91-1.9%$30.00+279.3%+31.8%$8.54M$1.83M-4.8230FBRXForte Biosciences3.7385 of 5 stars$6.11+4.6%$23.58+286.0%+33,920.0%$8.54MN/A-0.385Analyst RevisionNews CoverageEGRXEagle Pharmaceuticals1.127 of 5 stars$0.90+38.5%N/A-90.0%$8.45M$316.61M0.00134Gap UpGLTOGalecto3.2092 of 5 stars$6.02-5.3%$10.00+66.1%-60.6%$8.37MN/A-0.3140Gap DownHigh Trading Volume Related Companies and Tools Related Companies LCI Competitors RDHL Competitors NKGN Competitors ENSC Competitors SNGX Competitors JAGX Competitors ADXN Competitors FBRX Competitors EGRX Competitors GLTO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRTX) was last updated on 11/19/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
